All In MedTech

FDA Clearance Tracker · P130021-S155

Evolut FX+ TAV, Evolut FX DCS, Evolut FX LS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 22, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 22, 2024

Approved

Time to decision

56 days

Received Jan 26, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P130021-S155
Device name
Evolut FX+ TAV, Evolut FX DCS, Evolut FX LS
Applicant location
Miinneapolis, MN
Received
Jan 26, 2024
Decided
Mar 22, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P130021

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

Approval for design and manufacturing modifications to the Evolut FX System to incorporate larger openings in the stent frame. The device, as modified, will be marketed under the trade name Evolut FX+ System.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.